Clene Inc Ordinary Shares CLNN 深 滬
等待開盤 12-12 09:30:00 美东时间
6.88
+0.200
+2.99%
華盛通- 最 高7.03
- 今 開6.65
- 成交量 12.41万股
- 最 低 6.50
- 昨 收 6.68
- 總市值 7109.79万
- 52周最高 13.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.2801
- 委 比 -60.78%
- 總股本 1033.40万
- 歷史最高 356.40
- 量 比 0.36
- 振 幅 7.93%
- 歷史最低 2.2801
- 每 手 1
- 風險率 2.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Clene to Present at the Emerging Growth Conference
Clene Inc. and its subsidiary Clene Nanomedicine Inc. announced that management will present at the Emerging Growth Conference on December 10, 2025, at 4:25 p.m. ET. The presentation will be available as a webcast on Clene’s website and through the conference portal. Clene is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS and MS....
12-09 13:30
击败ABB，40亿美元并购电力系统公司
（来源：电能革新） 据知情人士透露，黑石集团即将收购麦克莱恩电力系统公司，该交易可能对这家电力零部件制造商的估值超过40亿美元。 这些要求匿名讨论保密信息的...
12-07 23:29
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Clene (NASDAQ:CLNN) stock increased by 10.0% to $7.94 during Wednesday'...
12-04 05:06
Clene Updates on CNM-Au8® ALS Program
The latest update is out from Clene ( ($CLNN) ). On December 3, 2025, Clene Inc...
12-03 22:18
Clene To Update Investors On CNM-Au8 ALS Program In December 3 Webcast At 8:30am ET
Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of
12-03 06:40
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
Clene Inc. and its subsidiary Clene Nanomedicine Inc. are clinical-stage biopharmaceutical companies focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS and MS. They announced participation in the Benchmark 14th Annual Discovery One-on-One Investor Conference on December 4, 2025, in New York, hosting 1x1 investor meetings.
11-20 13:00
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
11-17 21:31
Clene Q3 EPS $(0.85) Misses $(0.58) Estimate, Sales $15.000K Miss $55.143K Estimate
Clene (NASDAQ:CLNN) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.58) by 46.55 percent. This is a 30.33 percent increase over losses of $(1.22) per share from the same
11-13 21:09
